2008-11-04 新"類澱粉蛋白"示蹤劑 Amyloid imaging agent

張貼者:2008年11月4日 上午8:36林昆儒   [ 已更新 2008年11月4日 上午8:44 ]

Avid’s AV-45 是美國第一個進入臨床第二期研究的類澱粉蛋白新藥

 
Silver Spring, Maryland, October 23, 2008
 
Avid Radiopharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) Peripheral and CNS Advisory Committee provided strong support for development of amyloid imaging agents to test for the presence or absence of Alzheimer’s disease pathology in people with symptoms of cognitive impairment. Avid’s Phase II amyloid imaging compound, 18F-AV-45 (AV-45) is well positioned to rapidly enter late stage development based on the FDA Advisory Committee recommendations.
 
Avid is currently enrolling patients in clinical studies of 18F-PET agents for imaging amyloid plaques in Alzheimer’s disease and for imaging the vesicular monoamine transporter (VMAT2) in diseases such as Parkinson’s disease (PD), Dementia with Lewy Bodies (DLB) and Diabetes Mellitus (DM). More information about Avid is available at  www.avidrp.com.
Ċ
林昆儒,
2008年11月4日 上午8:41
Comments